Corcept Therapeutics Incorporated
CORT
Jodie situation report
Corcept Therapeutics Incorporated's move is being confirmed by its market group.
CORT accounts for 2.7% of the group's measured movement across 7.3 effective names. raw member direction is mixed; 6 of 10 SPY-adjusted paths align to the upside. Capital-flow agreement is 53%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
No material onset for CORT could be timestamped inside the aligned 5-minute window.
5 of 10 members in Cancer Diagnostics are active. 0 of 1 disclosed connections are confirming.
- At least 7 of 10 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as MYGN begins moving with the group.
Invalidation: The live read weakens if participation falls to 3 of 10 members or fewer.
Who this business touches
The relationships behind CORT
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
TEVATeva Pharmaceutical Industries LimitedcompetitorFeb 24, 2026 ▾
“Since January 2024, our Products also compete with a generic version of Korlym sold by Teva Pharmaceuticals USA, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
CORT is currently a Participant in the organic co-movement group Cancer Diagnostics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.